Company Profile For Biovail Corporation

Biovail Corporation (BVF.N) (New York Stock Exchange)

sector: Healthcare · industry: Pharmaceuticals - Generic & Specialty ·

As of 1:30am IST

14.45USD

Price Change

+0.22

Percent Change

+1.55%

Analyst Recommendations

Overview

Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. The Company has various research and development, clinical research, manufacturing and commercial operations located in Barbados, Canada, the United States and Puerto Rico. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. On September 16, 2008, Biovail acquired Prestwick Pharmaceuticals, Inc.

Quick Financial Synopsis

BRIEF: For the nine months ended 30 September 2009, Biovail Corporation's revenues increased 1% to $579.4M. Net income increased 30% to $103.4M. Revenues reflect increased income from product sales. Net income also reflects the absence of acquisition related cost, a decrease in legal settlements, the presence of foreign exchange gains vs. a loss and the absence of impairment losses on equity securities.